Adicet is actively discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Solid & Heme
Gammaretroviral and lentiviral vector manufacture: brief overview
Cell and Gene Therapy Insights | 2021
Effects of IL-2 and IL-15 on the proliferative and antitumor capacities of allogeneic anti-CD20 CAR-engineered γδ T cells in a 3D B cell lymphoma spheroid assay
SITC Poster | Spheroids 10 video | 2020
A Novel γδT Cell Product Targeting CD20 for the Treatment of B Cell Malignancies
ASGCT Poster | 2019